Thinking about holiday gatherings? Harvard Health experts weigh in
Harvard Health Publishing – November 22, 2021 Harvard Health Publishing faculty contributors, including Suzanne Salamon, MD (Geriatric Medicine, BIDMC), answered...
Harvard Health Publishing – November 22, 2021 Harvard Health Publishing faculty contributors, including Suzanne Salamon, MD (Geriatric Medicine, BIDMC), answered...
Harvard Medical School – November 19, 2021 In a recent phase 2b/3 clinical trial, a third mRNA vaccine against COVID-19 — known as CVnCoV and...
Bloomberg – November 17, 2021 The researchers studying the mid-summer COVID-19 outbreak in Provincetown are gaining important insights into the...
COVID-19 infections among vaccinated people are rising in the U.K. Dan Barouch, MD, PhD (Center for Virology and Vaccine Research, BIDMC) said breakthrough infections are not rare, unexpected, or very concerning.
In October, an expert panel that advises the CDC voted unanimously to approve boosters for specific groups and opened the door for mixing and matching vaccines. Westyn Branch-Elliman, MD (Infectious Disease, BIDMC) discussed how the decision was informed by a newly released NIH-funded study, which is yet to be peer-reviewed, that suggests mixing and matching vaccine boosters is safe and effective among 458 participants enrolled.
In his new book, A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, Wall Street Journal reporter Greg Zuckerman highlights stories of vaccine development, including mention of Dan Barouch, MD, PhD (Center for Virology and Vaccine Research, BIDMC) and his work with the Ad26 viral vector technology.
New research from BIDMC published Friday in the New England Journal of Medicine suggests the one-shot Johnson & Johnson vaccine produces a more durable immune response than the Pfizer-BioNTech and Moderna shots, which have been found to wane over time. Dan Barouch, MD, PhD (Center for Virology and Vaccine Research, BIDMC) will present the data for the first time to the FDA’s scientific advisory committee on Friday morning, hours before the panel is expected to issue a recommendation on J&J’s booster to the agency.
New research from BIDMC published Friday in the New England Journal of Medicine suggests the one-shot Johnson & Johnson vaccine produces a more durable immune response than the Pfizer-BioNTech and Moderna shots, which have been found to wane over time. Dan Barouch, MD, PhD (Center for Virology and Vaccine Research, BIDMC) said that by month eight, antibody responses were comparable for these three vaccines.
Amid Covid variants concerns, in some countries, people have already received booster shots of Pfizer-BioNTech or Moderna after getting two shots of either AstraZeneca, Sinopharm or Sinovac. Dan Barouch, MD, PhD (Center for Virology and Vaccine Research, BIDMC) said that theoretically, a person immunized with one vaccine and then boosted with another, “might be able to get the best of both worlds, but that no efficacy data on the approach is available yet.”
